Page 264 - Glucose Monitoring Devices

References 271

[13] Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacido-
sis in adults with type 1 diabetes: results from the T1D exchange clinic registry. The
Journal of Clinical Endocrinology and Metabolism 2013;98:3411e9.
[14] Munshi MN, Slyne C, Segal AR, et al. Liberating A1C goals in older adults may not
protect against the risk of hypoglycemia. Journal of Diabetic Complications 2017;31:
1197e9.
[15] Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ,
Budnitz DS. National estimates of insulin-related hypoglycemia and errors leading to
emergency department visits and hospitalizations. JAMA Internal Medicine 2014;
174:678e86.
[16] Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia
in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014;63:1738e47.
[17] Whitmer RA, Karter AJ, Yaffe K, Quesenberry Jr CP, Selby JV. Hypoglycemic episodes
and risk of dementia in older patients with type 2 diabetes mellitus. Journal of the Amer-
ican Academy of Dermatology 2009;301:1565e72.
[18] Garg SK, Moser EG. How basal insulin analogs have changed diabetes care. Diabetes
Technology and Therapeutics 2011;13(Suppl. 1). S-1eS-4.
[19] Dı ´ez-Ferna ´ndez A, Cavero-Redondo I, Moreno-Ferna ´ndez J, Pozuelo-Carrascosa DP,
Garrido-Miguel M, Martı ´nez-Vizcaı ´no V. Effectiveness of insulin glargine U-300
versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in
type 1 and type 2 diabetes: a systematic review and meta-analysis. Acta Diabetologica
December 3, 2018. https://doi.org/10.1007/s00592-018-1258-0.
[20] Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT,
Nielsen TSS, Warren M, Group Information, SWITCH 1. Effect of insulin degludec
vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the
SWITCH 1 randomized clinical trial. Journal of the American Academy of Derma-
tology July 4, 2017;318(1):33e44.
[21] Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN,
Kvist K, Norwood P. Effect of insulin degludec vs insulin glargine U100 on hypogly-
cemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. Journal
of the American Academy of Dermatology July 4, 2017;318(1):45e56.
[22] Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U,
Boettcher C, Kapellen T, Rosenbauer J, Holl RW. Association of insulin pump therapy
vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic con-
trol among children, adolescents, and young adults with type 1 diabetes. Journal of the
American Academy of Dermatology October 10, 2017;318(14):1358e66.
[23] Adolfsson P, Rentoul D, Klinkenbijl B, Parkin CG. Hypoglycaemia remains the key
obstacle to optimal glycaemic control e continuous glucose monitoring is the
solution. European Endocrinology September 2018;14(2):50e6.
[24] Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM,
Bhargava A, Bode BW, Haller S, Kruger DF, McGill JB, Polonsky W, Price D,
Toschi E, DIAMOND Study Group. Effect of initiating use of an insulin pump in adults
with type 1 diabetes using multiple daily insulin injections and continuous glucose
monitoring (DIAMOND): a multicentre, randomised controlled trial. The Lancet Dia-
betes and Endocrinology September 2017;5(9):700e8.
[25] Foster N, Beck RW, Miller KM, Clements MA, Rickels MR, et al. State of type 1 dia-
betes management and outcomes from the T1D exchange in 2016e2018. Diabetes
Technology and Therapeutics 2019;21(2):66e72.